tiprankstipranks
The Fly

Y-mAbs Therapeutics sees annual cash burn $15M-$20M

Y-mAbs Therapeutics sees annual cash burn $15M-$20M

FY24 anticipated operating expenses expected to remain between $115M-$120M; Cash and cash equivalents anticipated to continue to support operations as currently planned into 2027.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com